Revolutionizing Autoimmune Treatment: Zenas BioPharma's Breakthrough Quarter

Meridian Small Cap Growth Fund's Q4 2025 Review: A Look at Market Dynamics and Zenas BioPharma's Impact

The fourth quarter of 2025 saw U.S. equity markets influenced by a blend of optimism for monetary easing and cautious sentiments regarding economic growth and valuations. Early in the quarter, robust earnings from AI-related sectors and the Federal Reserve's interest rate cut in October fueled positive expectations for financial conditions. However, market enthusiasm moderated as the quarter progressed. Despite this, the quarter contributed positively to the overall annual performance, with small-cap stocks achieving a 12.8% annual return, including a 2.2% gain in Q4. During this period, value stocks outpaced growth stocks, according to Russell indices. The Meridian Small Cap Growth Fund recorded a net return of 0.90% in Q4 2025, slightly trailing the Russell 2000 Growth Index's 1.22% return.

Zenas BioPharma's Stellar Performance: Driven by Clinical Success and Investor Confidence

Zenas BioPharma, Inc. (NASDAQ: ZBIO) emerged as a notable highlight in the Meridian Small Cap Growth Fund's fourth-quarter 2025 investor letter. As a clinical-stage biopharmaceutical company, Zenas BioPharma focuses on developing groundbreaking therapies for autoimmune diseases. The company demonstrated impressive market performance, with its shares gaining 30.78% in a single month and an astonishing 241.61% over the past 52 weeks. As of February 18, 2026, Zenas BioPharma's stock closed at $26.68 per share, reaching a market capitalization of $1.432 billion.

Obexelimab's Promising Future: Advancing Autoimmune Therapies

Meridian Small Cap Growth Fund specifically commended Zenas BioPharma, Inc. for the encouraging Phase II trial data of its lead drug, Obexelimab. This drug, currently in Phase 3 clinical trials, is on track for potential approval and launch by 2027. The strong performance of the stock during the quarter was directly attributed to these positive trial results. While acknowledging the inherent volatility of share prices for clinical-stage companies, which often fluctuate with individual data releases, the fund emphasized its focus on Zenas BioPharma's long-term revenue potential. With multiple indications under development, the company holds the promise of achieving annual revenues exceeding $1 billion, contingent upon successful development and regulatory approvals.

Investment Landscape: Zenas BioPharma Amidst Hedge Fund Holdings and AI Opportunities

Despite its significant progress, Zenas BioPharma, Inc. (NASDAQ: ZBIO) was not among the top 30 most popular stocks among hedge funds at the end of the third quarter, with 13 hedge fund portfolios holding the stock, a number consistent with the previous quarter. While recognizing Zenas BioPharma's investment potential, some analysts suggest that certain AI stocks may offer greater upside potential with reduced downside risk. The market continues to evolve, presenting diverse opportunities for investors.